Traders Buy Shares of Becton Dickinson and (BDX) on Weakness

Traders purchased shares of Becton Dickinson and Co (NYSE:BDX) on weakness during trading on Thursday. $142.71 million flowed into the stock on the tick-up and $126.10 million flowed out of the stock on the tick-down, for a money net flow of $16.61 million into the stock. Of all stocks tracked, Becton Dickinson and had the 30th highest net in-flow for the day. Becton Dickinson and traded down ($4.90) for the day and closed at $245.10

A number of equities research analysts have recently commented on the company. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. Citigroup raised Becton Dickinson and from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $237.00 to $251.00 in a report on Tuesday, April 10th. Finally, JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective for the company in a report on Thursday, June 21st. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $240.88.

The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. The company has a market cap of $66.90 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.74 and a beta of 1.13.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. The firm had revenue of $4.28 billion during the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The firm’s quarterly revenue was up 41.0% on a year-over-year basis. During the same period last year, the company posted $2.46 EPS. sell-side analysts predict that Becton Dickinson and Co will post 10.99 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s payout ratio is currently 31.65%.

In other news, Director David F. Melcher purchased 500 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was purchased at an average cost of $225.07 per share, with a total value of $112,535.00. Following the purchase, the director now owns 2,728 shares in the company, valued at approximately $613,990.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexandre Conroy sold 20,128 shares of the stock in a transaction on Monday, May 21st. The shares were sold at an average price of $228.74, for a total value of $4,604,078.72. Following the transaction, the insider now directly owns 35,583 shares of the company’s stock, valued at $8,139,255.42. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Sustainable Growth Advisers LP acquired a new stake in shares of Becton Dickinson and during the 1st quarter valued at $166,282,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Becton Dickinson and during the 1st quarter valued at $87,368,000. The Manufacturers Life Insurance Company lifted its position in shares of Becton Dickinson and by 61.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,033,592 shares of the medical instruments supplier’s stock valued at $223,979,000 after acquiring an additional 393,135 shares during the last quarter. CI Investments Inc. acquired a new stake in shares of Becton Dickinson and during the 1st quarter valued at $75,520,000. Finally, Northern Trust Corp lifted its position in shares of Becton Dickinson and by 8.1% during the 1st quarter. Northern Trust Corp now owns 3,319,529 shares of the medical instruments supplier’s stock valued at $719,341,000 after acquiring an additional 247,339 shares during the last quarter. 84.16% of the stock is owned by hedge funds and other institutional investors.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Diversification Important in Investing

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply